From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation
Dheeraj Soni, Francesco Borriello, David A. Scott, Frédéric Féru, Maria De Leon, Spencer E. Brightman, Wing Ki Cheng, Gandolina Melhem, Jennifer A. Smith, Juan Carlos Ramı́rez, Soumik Barman, Michael D. Cameron, Aisling Kelly, Kristina Walker, Etsuro Nanishi, Simon D. van Haren, Tony Phan, Yizhi Qi, Robert Kinsey, Michal M. Raczy, Al Ozonoff, Matthew A. Pettengill, Jeffery A. Hubbell, Christopher B. Fox, David J. Dowling, Ofer Levy
Abstract
Vaccination can help prevent infection and can also be used to treat cancer, allergy, and potentially even drug overdose. Adjuvants enhance vaccine responses, but currently, the path to their advancement and development is incremental. We used a phenotypic small-molecule screen using THP-1 cells to identify nuclear factor-κB (NF-κB)-activating molecules followed by counterscreening lead target libraries with a quantitative tumor necrosis factor immunoassay using primary human peripheral blood mononuclear cells. Screening on primary cells identified an imidazopyrimidine, dubbed PVP-037. Moreover, while PVP-037 did not overtly activate THP-1 cells, it demonstrated broad innate immune activation, including NF-κB and cytokine induction from primary human leukocytes in vitro as well as enhancement of influenza and SARS-CoV-2 antigen-specific humoral responses in mice. Several de novo synthesis structural enhancements iteratively improved PVP-037's in vitro efficacy, potency, species-specific activity, and in vivo adjuvanticity. Overall, we identified imidazopyrimidine Toll-like receptor-7/8 adjuvants that act in synergy with oil-in-water emulsion to enhance immune responses.